title: Protective effect of edaravone against tobramycin-induced ototoxicity.
abstract: CONCLUSIONS
  It is suggested that simultaneous treatment with the radical scavenger edaravone has an effective protective effect against tobramycin ototoxicity in rat. Even if the edaravone treatment is postponed for 7 days, it can still prevent hearing loss, but a 14 day delay cannot protect from ototoxicity.
  
  
  OBJECTIVE
  With the aim of alleviating hearing loss caused by aminoglycoside ototoxicity, we performed a trial to assess the hearing protective efficacy of the radical scavenger edaravone.
  
  
  METHODS
  In part one of the study, 21 male Sprague-Dawley albino rats were used; 2 rats served as controls for the safety of edaravone. Eight rats each received 10 subcutaneous injections (s.c.) of tobramycin (160 mg/kg b.w.) once daily and saline injection intraperitoneally for 2 weeks. Eleven rats were given 10 s.c. tobramycin injections simultaneously with an intraperitoneal injection of edaravone (3 mg/kg b.w.). In part two, tobramycin was injected in 13 rats (as above). Five of these received two edaravone injections 7 days later and four rats similarly 14 days later. Auditory brainstem response (ABR) was used to assess hearing.
  
  
  RESULTS
  All rats treated only with tobramycin showed a deterioration of hearing. None of the rats given simultaneous treatment with tobramycin and edaravone demonstrated hearing loss. A 7 day delay in edaravone injection still prevented hearing loss, but a 14 day delay had only a temporary prophylactic effect.
authors.affiliation: Department of Otolaryngology, Head & Neck Surgery, University Hospital, Uppsala, Sweden. monika.stenkvist.asplund@akademiska.se
authors.forename: Monika Stenkvist
authors.initials: MS
authors.lastname: Asplund
authors.forename: Adnan
authors.initials: A
authors.lastname: Lidian
authors.forename: Birgitta
authors.initials: B
authors.lastname: Linder
authors.forename: Masaya
authors.initials: M
authors.lastname: Takumida
authors.forename: Matti
authors.initials: M
authors.lastname: Anniko
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D000077553:Edaravone; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006313:Hearing Loss, Central / Q000139:chemically induced / Q000517:prevention & control; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D014031:Tobramycin / Q000633:toxicity*
chemical_list: D000900:Anti-Bacterial Agents; D016166:Free Radical Scavengers; D017382:Reactive Oxygen Species; D000077553:Edaravone; D000983:Antipyrine; D014031:Tobramycin